Seeking Alpha

Vivus (VVUS +5%) spikes as the FDA approves its amendment and modification to the Risk...

Vivus (VVUS +5%) spikes as the FDA approves its amendment and modification to the Risk Evaluation and Mitigation Strategy for Qsymia. The amendment, which was submitted last October, allows Qsymia to be dispensed through certified retail pharmacies in addition to the existing network of certified mail-order pharmacies, which reduces the prescribing burden for physicians and waiting times for patients seeking to initiate therapy.
From other sites
Comments (5)
  • user418
    , contributor
    Comments (258) | Send Message
     
    Now that VVUS is on par with ARNA how much longer will the DEA continue to hold up ARNA?
    16 Apr 2013, 09:11 PM Reply Like
  • nomis_simon
    , contributor
    Comments (170) | Send Message
     
    Who knows, who cares. How much does this hurt though? After all the bull that you sputter on these comment sections about Vivus' weaknesses, I love it that your precious belviq still sits on the sidelines. $200 for half the efficacy? No more retail pharmacy advantage bologna. Enjoy.
    16 Apr 2013, 10:38 PM Reply Like
  • gm2b
    , contributor
    Comments (38) | Send Message
     
    What are you going to say or do if and when retail sales don't go up now? Be careful what you wish for, don't forget, you can still buy the same two components of Q for 1/4 the price as presently advertised.
    17 Apr 2013, 12:32 AM Reply Like
  • Sedric
    , contributor
    Comments (1771) | Send Message
     
    Since these RX's are for long term usage i don't think this change will effect sales in any dramatic way. Mail order is convenient . Dont need to stand in line at the pharma
    17 Apr 2013, 12:11 AM Reply Like
  • Qnexerin
    , contributor
    Comments (67) | Send Message
     
    It really doesn't matter. If they continue to NOT market it well, potential customers aren't even aware of it. Until I see a Qsymia commercial, I will continue to be a VIVUS non-believer. Arena on the otherhand just needs the greenlight for Easai to run their commercials and in no time the funds will flourish!
    17 Apr 2013, 07:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs